Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 17, 2007 Andrew R. Vaino	Problems Posed for Pozen If its latest drug isn't approved, the pharmaceutical's stock will clearly tank. Any benefits stemming from the drug's successful approval are harder to gauge.
The Motley Fool October 8, 2007 Brian Orelli	Pozen Submits Safety Data Will Pozen's response to its second approvable letter be enough? Investors may want to take this with a grain of salt.
The Motley Fool August 3, 2007 Brian Orelli	Another Headache for Pozen Investors Drugmaker Pozen might have to run one more trial for the FDA for its migraine drug.
BusinessWeek February 27, 2006 Gene G. Marcial	Pozen's Trexima: Going To Market With Glaxo Pozen's Trexima is a new drug for severe headaches that analysts claim is more effective and faster-acting than GlaxoSmithKline's $1 billion-a-year blockbuster Imitrex.
The Motley Fool August 3, 2006 S.J. Caplan	AstraZeneca's Path to Avoid Pain The pharmaceutical giant partners with Pozen to co-develop a drug. Take heart, AstraZeneca shareholders! No queasy stomachs are expected in your future.
The Motley Fool April 17, 2008 Brian Orelli	Headache Over for Pozen and Glaxo? The duo's FDA headache regarding their migraine drug is over, but a new one is about to begin.
The Motley Fool May 3, 2010 Brian Orelli	While You Were Reveling in Dendreon's Win The FDA has approved Vimovo, an arthritis drug from Pozen and AstraZeneca, and Bristol-Myers Squibb also got a decision from the FDA, but it wasn't the positive kind.
The Motley Fool February 24, 2011 Brian Orelli	Youth in Revolt Against POZEN POZEN fails to get a pediatric extension on its migraine drug.
The Motley Fool March 4, 2010 Brian Orelli	A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan.
The Motley Fool June 2, 2004 Roger Nusbaum	POZEN Is a Poser Here's a great example of the riskiest type of biotech stock.
The Motley Fool May 1, 2007 Mike Havrilla	Heads Up, Biotech Investors Big news is in the offing for these companies. Pozen... Progenics... Zymogenetics... etc.
The Motley Fool June 30, 2008 Brian Orelli	A Drug to End Merck's Headache? Merck presents promising data for its phase 3 migraine drug.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool December 4, 2008 Brian Orelli	Poor Pozen It's not often that you see a drug developer release data from two positive phase 3 trials for its lead pipeline compound and see its shares fall more than 4%, but that's what happened to Pozen.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool January 16, 2008 Brian Orelli	Headache Almost Over for Pozen The drug is safe; hopefully that's all the FDA wanted to know.
The Motley Fool November 26, 2011 Stephanie Baum	Pozen Inks $75 Million Royalty Deal for Treximet The pharma sells U.S. rights for the migraine drug to Canada's national pension fund.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool April 16, 2011	Pozen Wins Injunction Blocking Generic Migraine Drug The ruling against Par Pharmaceutical comes just in time for Pozen.
The Motley Fool August 17, 2007 Brian Orelli	Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
BusinessWeek December 29, 2010 Kelley & Cortez	AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool July 30, 2010 Cliff D'Arcy	Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline.
The Motley Fool October 14, 2010 Sean Williams	Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away.
The Motley Fool August 10, 2010 Brian Orelli	When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
The Motley Fool September 17, 2011 Chris Seper	Pozen's Digital Marketing Plan: A Prescription for the Pharma Industry? The company looks to get in tune with social media.
The Motley Fool February 3, 2011 Owain Bennallack	Glaxo Sweetens a Bitter Pill The drugmaker reports a loss, but resumes share buybacks.
BusinessWeek June 2, 2011 Kresge & Connolly	A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies.
The Motley Fool October 16, 2007 Brian Orelli	Pozen Hedges Its Bets As promised, Pozen and partner GlaxoSmithKline announce that the pair have submitted a response to their approvable letter for Trexima, and that they plan to do an additional just-in-case safety trial.
The Motley Fool April 10, 2008 Brian Lawler	Glaxo Angers the FDA GlaxoSmithKline announces that the FDA has sent it a warning letter regarding its failure to meet certain post-marketing requirements for Avandia.
The Motley Fool January 28, 2011 Alan Oscroft	AstraZeneca to Double Buybacks Regulatory setbacks have hit the drug firm's profits, but things look pretty resilient overall.
BusinessWeek January 31, 2005 Kerry Capell	No Relief For AstraZeneca More bad news about potential blockbusters weakens Europe's third-largest drugmaker. Analysts say the only thing keeping Astra's shares from going into free fall is the mounting speculation that GSK might make a play for the troubled drugmaker.
The Motley Fool February 14, 2005 Stephen D. Simpson	Glaxo Stays Above the Fray The British drugmaker looks to regain momentum this year. Investors who are comfortable with the general industry risks and are looking for a relatively "clean" pharmaceutical company should do some research on Glaxo shares.
The Motley Fool December 16, 2011 Brian Orelli	Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value.
The Motley Fool April 26, 2007 Brian Lawler	AstraZeneca's Announcement Overshadows Earnings AstraZeneca releases first-quarter financial results. Investors, take note.
American Family Physician October 15, 2000 Sharon Scott Morey	Practice Guidelines Guidelines on Migraine: Part 2. General Principles of Drug Therapy...
Chemistry World April 15, 2015 Christopher Barnard	Hydrogel with a basic instinct for drug delivery A self-assembling hydrogel with nanofibers that specifically capture and release anti-inflammatory compounds has been created for applications in targeted drug delivery.
The Motley Fool November 18, 2009 Jennifer Schonberger	Cleaning Up the Crisis MFS Investment Management chairman and author Bob Pozen discusses the current state of the economy.
American Family Physician January 1, 2006 MODI Lowder	Medications for Migraine Prophylaxis Sufficient evidence and consensus exist to recommend propranolol, timolol, amitriptyline, divalproex, sodium valproate, and topiramate as first-line agents for migraine prevention.
The Motley Fool December 28, 2005 Stephen D. Simpson	AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either.